

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 1, 2010

NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

0-24006
(Commission
File Number)

94-3134940
(IRS Employer
Identification No.)

201 Industrial Road
San Carlos, California 94070
(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: (650) 631-3100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d) On February 1, 2010, R. Scott Greer was appointed to the board of directors of Nektar Therapeutics, a Delaware corporation (the “Company”), as a Class III Director whose initial term will end at our 2010 Annual Meeting of Stockholders. Our board has determined that Mr. Greer is an independent director as that term is defined by the Securities and Exchange Commission and the Nasdaq Stock Market, Inc. The board has not yet determined on which board committees Mr. Greer will serve.

Mr. Greer, age 51, currently serves as Managing Director of Numenor Ventures, LLC, a venture capital firm. In 1996, Mr. Greer co-founded Abgenix, Inc., a company that specialized in the discovery, development and manufacture of human therapeutic antibodies, and from June 1996 through May 2002, he served as its Chief Executive Officer. He also served as a director of Abgenix from 1996 and Chairman of the board of directors from 2000 until the acquisition of Abgenix by Amgen, Inc. in April 2006. Prior to Abgenix’s formation, Mr. Greer held senior management positions at Cell Genesys, Inc., a biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development, and various positions at Genetics Institute, Inc., a biotechnology research and development company. Since May 2003, Mr. Greer has served as Chairman of the board of directors of Acologix, Inc., a privately-held development-stage biotechnology company and, since May 2000, as a director of Acologix. Mr. Greer served as Chairman of the board of directors of Sirna Therapeutics, Inc., a biotechnology company, from 2003 until its merger with Merck & Co., Inc. in December 2006. Mr. Greer received a B.A. in Economics from Whitman College and an M.B.A. degree from Harvard University. Mr. Greer also was a certified public accountant.

There are no arrangements or understandings between Mr. Greer and any other persons pursuant to which he was selected as a director. There are no current or proposed transactions between the Company and Mr. Greer or his immediate family members that would require disclosure under Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission.

Mr. Greer will participate in the Company’s Amended and Restated Compensation Plan for Non-Employee Directors (the “Plan”), previously filed on December 14, 2009, with the Securities and Exchange Commission as Exhibit 10.1 to the Current Report on Form 8-K. Our non-employee directors are eligible to participate in the Plan.

Item 7.01. Regulation FD Disclosure

On February 2, 2010, the Company issued a press release announcing the appointment of Mr. Greer to the board of directors, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits:

Exhibit No.	Description
99.1	Press release issued by Nektar Therapeutics on February 2, 2010 entitled “Nektar Therapeutics Appoints R. Scott Greer to Board of Directors.”

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued by Nektar Therapeutics on February 2, 2010 entitled "Nektar Therapeutics Appoints Scott Greer to Board of Directors."

News Release

Nektar Therapeutics Appoints R. Scott Greer to Board of Directors

San Carlos, Calif., February 2, 2010 – Nektar Therapeutics (Nasdaq: NKTR) today announced that R. Scott Greer has joined the company's Board of Directors. Mr. Greer is an accomplished industry leader with more than 25 years of experience in the biopharmaceutical industry. The addition of Mr. Greer brings the total number of Nektar Board members to nine.

"Scott's wealth of strategic and operational experience will serve as a valued addition to our Board," said Howard W. Robin, President and Chief Executive Officer of Nektar and member of the Board of Directors. "The guidance and insight of successful leaders like Scott help support our strategic business objectives as we drive multiple programs through the clinic and continue to build shareholder value."

Mr. Greer is currently Managing Director of Numenor Ventures, LLC, where he has made direct investments in nearly twenty healthcare, technology, and consumer product companies. Mr. Greer founded Abgenix, Inc., a biotechnology company focused on developing human antibody-based therapeutics. He served as Abgenix's Chief Executive Officer from 1996 to 2002, and its Chairman from 2000 to 2006 when the company was acquired by Amgen, Inc. for approximately \$2.2 billion. Mr. Greer invested in and served as Chairman of the Board of Sirna Therapeutics, a publicly-traded biotechnology company that was sold to Merck for more than \$1.1 billion in December 2006. Prior to forming Abgenix, Mr. Greer spent five years at Cell Genesys, Inc., initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development. Mr. Greer is currently Chairman of the Board of Acologix, Inc., a development-stage biotechnology company and in the past has served on the boards of numerous public and private life sciences companies. Mr. Greer has a B.A. in economics from Whitman College and an M.B.A. from Harvard University.

"Nektar possesses a powerful drug development platform, a rich and deep pipeline and a strong financial position. I look forward to working with Howard and the Board to support the company's continued success as it capitalizes on its proven polymer conjugate technology across multiple therapeutic areas," said Mr. Greer.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar recently entered into an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at <http://www.nektar.com>.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's technology platform, Nektar's pipeline of product candidates in development, and certain of Nektar's collaborations with third parties. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) Nektar's proprietary product candidates and those of its partners are in the early to mid-stage phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval; (ii) Nektar or its partners may not be able to successfully obtain regulatory approval for product candidates in development; (iii) Nektar's commercialization partners may not be successful in their sales and marketing efforts even if current product candidates successfully receive future regulatory approval in one or more markets; (iv) Nektar's patent applications for its technology platforms and proprietary or partner product candidates may not issue, patents that have issued may not be enforceable; and/or intellectual property licenses from third parties may be required in the future as a result of litigation or otherwise; and (v) other important risks and uncertainties set forth in Nektar's most recent Quarterly Report on Form 10-Q filed on November 5, 2009 and its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2009. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:

Jennifer Ruddock/Nektar Therapeutics

(650) 631-4954

Susan Noonan/SAN Group

(212) 966-3650

Nektar Media Inquiries:

Karen Bergman/BCC Partners

(650) 575-1509

Michelle Corral/BCC Partners

(415) 794-8662

###
